These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9229361)

  • 21. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.
    Lu LD; Stump KL; Wallace NH; Dobrzanski P; Serdikoff C; Gingrich DE; Dugan BJ; Angeles TS; Albom MS; Mason JL; Ator MA; Dorsey BD; Ruggeri BA; Seavey MM
    J Immunol; 2011 Oct; 187(7):3840-53. PubMed ID: 21880982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunomodulating effect of a traditional Japanese medicine, hachimi-jio-gan (ba-wei-di-huang-wan), on Th1 predominance in autoimmune MRL/MP-lpr/lpr mice.
    Furuya Y; Kawakita T; Nomoto K
    Int Immunopharmacol; 2001 Mar; 1(3):551-9. PubMed ID: 11367538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma levels of nucleosomes and nucleosome-autoantibody complexes in murine lupus: effects of disease progression and lipopolyssacharide administration.
    Licht R; van Bruggen MC; Oppers-Walgreen B; Rijke TP; Berden JH
    Arthritis Rheum; 2001 Jun; 44(6):1320-30. PubMed ID: 11407691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of cyclophosphamide on leukocytic infiltration in the brain of MRL/lpr mice.
    Farrell M; Sakić B; Szechtman H; Denburg JA
    Lupus; 1997; 6(3):268-74. PubMed ID: 9104735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of (S)-armepavine from Nelumbo nucifera on autoimmune disease of MRL/MpJ-lpr/lpr mice.
    Liu CP; Tsai WJ; Shen CC; Lin YL; Liao JF; Chen CF; Kuo YC
    Eur J Pharmacol; 2006 Feb; 531(1-3):270-9. PubMed ID: 16413531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS).
    Katzav A; Kloog Y; Korczyn AD; Niv H; Karussis DM; Wang N; Rabinowitz R; Blank M; Shoenfeld Y; Chapman J
    Clin Exp Immunol; 2001 Dec; 126(3):570-7. PubMed ID: 11737078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice.
    Kulkarni OP; Sayyed SG; Kantner C; Ryu M; Schnurr M; Sárdy M; Leban J; Jankowsky R; Ammendola A; Doblhofer R; Anders HJ
    Am J Pathol; 2010 Jun; 176(6):2840-7. PubMed ID: 20413687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic lupus erythematosus onset in lupus-prone B6.MRL/lpr mice Is influenced by weight gain and Is preceded by an increase in neutrophil oxidative burst activity.
    Toller-Kawahisa JE; Canicoba NC; Venancio VP; Kawahisa R; Antunes LM; Cunha TM; Marzocchi-Machado CM
    Free Radic Biol Med; 2015 Sep; 86():362-73. PubMed ID: 26117329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IL-12-encoding plasmid has a beneficial effect on spontaneous autoimmune disease in MRL/MP-lpr/lpr mice.
    Hagiwara E; Okubo T; Aoki I; Ohno S; Tsuji T; Ihata A; Ueda A; Shirai A; Okuda K; Miyazaki J; Ishigatsubo Y
    Cytokine; 2000 Jul; 12(7):1035-41. PubMed ID: 10880249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B7 costimulation in the development of lupus: autoimmunity arises either in the absence of B7.1/B7.2 or in the presence of anti-b7.1/B7.2 blocking antibodies.
    Liang B; Gee RJ; Kashgarian MJ; Sharpe AH; Mamula MJ
    J Immunol; 1999 Aug; 163(4):2322-9. PubMed ID: 10438978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice.
    Gu Z; Akiyama K; Ma X; Zhang H; Feng X; Yao G; Hou Y; Lu L; Gilkeson GS; Silver RM; Zeng X; Shi S; Sun L
    Lupus; 2010 Nov; 19(13):1502-14. PubMed ID: 20647254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amelioration of systemic lupus erythematosus by Withangulatin A in MRL/lpr mice.
    Sun L; Zhou L; Chen M; Zhong R; Liu J
    J Cell Biochem; 2011 Sep; 112(9):2376-82. PubMed ID: 21520246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
    J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of administration of apoptotic blebs on disease development in lupus mice.
    Fransen JH; Berden JH; Koeter CM; Adema GJ; Van Der Vlag J; Hilbrands LB
    Autoimmunity; 2012 Jun; 45(4):290-7. PubMed ID: 22390780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment with lysophosphatidic acid improves glomerulonephritis through the suppression of macrophage activation in a murine model of systemic lupus erythematosus.
    Nagata W; Takayama E; Nakagawa K; Koizumi A; Ohsawa Y; Goto H; Yamashiro A; Ishinoda Y; Tanoue K; Kumagai H; Oshima N; Ishizuka T
    Clin Exp Rheumatol; 2024 Mar; 42(3):658-665. PubMed ID: 38436267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.
    Pérez de Lema G; Maier H; Franz TJ; Escribese M; Chilla S; Segerer S; Camarasa N; Schmid H; Banas B; Kalaydjiev S; Busch DH; Pfeffer K; Mampaso F; Schlöndorff D; Luckow B
    J Am Soc Nephrol; 2005 Dec; 16(12):3592-601. PubMed ID: 16267157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High titer anti-basement membrane antibodies in a subset of patients with pediatric systemic lupus erythematosus.
    Orjuela A; Suwanichkul A; Canter D; Minard CG; Devaraj S; Hicks MJ; Muscal E; Wenderfer SE
    Am J Nephrol; 2015; 41(3):241-7. PubMed ID: 25926050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice.
    Schwarting A; Wada T; Kinoshita K; Tesch G; Kelley VR
    J Immunol; 1998 Jul; 161(1):494-503. PubMed ID: 9647261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL lpr/lpr mice.
    Apelgren LD; Bailey DL; Fouts RL; Short L; Bryan N; Evans GF; Sandusky GE; Zuckerman SH; Glasebrook A; Bumol TF
    Cell Immunol; 1996 Oct; 173(1):55-63. PubMed ID: 8871601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Combined mesenchymal stem cells and allogenic bone marrow transplantation in treatment of MRL/lpr mice].
    Zhang GF; Zhang X; Dong GF
    Zhonghua Nei Ke Za Zhi; 2008 Sep; 47(9):754-7. PubMed ID: 19080203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.